These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9951955)

  • 61. Risedronate: clinical usage.
    Chapurlat RD; Delmas PD
    Int J Clin Pract; 2001 May; 55(4):275-8. PubMed ID: 11406915
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy.
    Fraser WD; Logue FC; Gallacher SJ; O'Reilly DS; Beastall GH; Ralston SH; Boyle IT
    Bone Miner; 1991 Feb; 12(2):113-21. PubMed ID: 1849762
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
    Miller PD; Epstein S; Sedarati F; Reginster JY
    Curr Med Res Opin; 2008 Jan; 24(1):207-13. PubMed ID: 18042311
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases.
    Rosen CJ; Kessenich CR
    Drugs; 1996 Apr; 51(4):537-51. PubMed ID: 8706593
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact of oral ibandronate 150 mg once monthly on bone structure and density in post-menopausal osteoporosis or osteopenia derived from in vivo μCT.
    Bock O; Börst H; Beller G; Armbrecht G; Degner C; Martus P; Roth HJ; Felsenberg D
    Bone; 2012 Jan; 50(1):317-24. PubMed ID: 22067902
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease.
    Heidenreich A; Ohlmann CH
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):991-1005. PubMed ID: 15606328
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
    J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of bisphosphonates on the increase in bone resorption induced by a low calcium diet.
    Antic VN; Fleisch H; Mühlbauer RC
    Calcif Tissue Int; 1996 Jun; 58(6):443-8. PubMed ID: 8661487
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Clinical trial on ibandronate in patients with tumor-associated hypercalcemia].
    Wang T; Song ST; Jiang ZF; Bian SG; Wang YJ; Li LQ; Zhu J
    Zhonghua Zhong Liu Za Zhi; 2004 Dec; 26(12):739-41. PubMed ID: 15733393
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Review of ibandronate in the treatment of osteoporosis.
    Chapurlat RD; Delmas PD
    Expert Opin Pharmacother; 2003 Mar; 4(3):391-6. PubMed ID: 12614191
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Bisphosphonates in the treatment of osteoporosis.
    Bell NH; Johnson RH
    Endocrine; 1997 Apr; 6(2):203-6. PubMed ID: 9225137
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.
    Delmas PD; Adami S; Strugala C; Stakkestad JA; Reginster JY; Felsenberg D; Christiansen C; Civitelli R; Drezner MK; Recker RR; Bolognese M; Hughes C; Masanauskaite D; Ward P; Sambrook P; Reid DM
    Arthritis Rheum; 2006 Jun; 54(6):1838-46. PubMed ID: 16729277
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.
    van Breukelen FJ; Bijvoet OL; Frijlink WB; Sleeboom HP; Mulder H; van Oosterom AT
    Calcif Tissue Int; 1982 Jul; 34(4):321-7. PubMed ID: 6814719
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy and safety of drugs for Paget's disease of bone.
    Reginster JY; Lecart MP
    Bone; 1995 Nov; 17(5 Suppl):485S-488S. PubMed ID: 8573423
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy.
    Sauty A; Pecherstorfer M; Zimmer-Roth I; Fioroni P; Juillerat L; Markert M; Ludwig H; Leuenberger P; Burckhardt P; Thiebaud D
    Bone; 1996 Feb; 18(2):133-9. PubMed ID: 8833207
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast.
    Tankó LB; McClung MR; Schimmer RC; Mahoney P; Christiansen C
    Bone; 2003 Apr; 32(4):421-6. PubMed ID: 12689686
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
    Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE
    Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
    Rossini M; Viapiana O; Gatti D; Adami S
    Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.